Clinical Trial Update: Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis) [Phase 4]

View source ↗

Summary

Phase 4 study evaluating immune reactivity of liquid and lyophilized Palivizumab (Synagis) formulations. Results were posted in 2008.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Disease

Drugs mentioned

• Synagis (palivizumab)

Snippet

Sponsor: MedImmune LLC | Conditions: Chronic Lung Disease | Phase 4 | Status: COMPLETED | Results posted: 2008-10-28